Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Future Oncol. 2012 Apr;8(4):403–414. doi: 10.2217/fon.12.22

Figure 1. Inhibitors of VEGF-A, -B, -C/D, and their receptors.

Figure 1

Bevacizumab is a monoclonal antibody against VEGF-A. VEGF and VEGF-C/D traps are fusion proteins that bind to VEGF-A, or VEGF-C/D, respectively. Ramucirumab (IMC-1121B) and IMFC-3C5 are monoclonal antibodies against VEGF receptor-2 and VEGF receptor-3, respectively. Thick arrows express major pathways and thin arrows express reported, but minor, pathways.

Ab: Antibody; VEGFR: VEGF receptor.